Catalog No.
DHD72801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-lambda
Clonality
Monoclonal
Target
ACVR2, ACTRIIA, ACTR-IIA, Activin receptor type IIA, ACVR2A, Activin receptor type-2A, ACTR-IIB, Activin receptor type IIB, Activin receptor type-2B, ACVR2B
Concentration
1.99 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P27037 & Q13705
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BYM338, CAS: 1356922-05-8
Clone ID
Bimagrumab
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial, PMID: 33074327
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial, PMID: 33439265
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial, PMID: 31397289
A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab, PMID: 30238817
Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes, PMID: 29566437
Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort, PMID: 33264516
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis, PMID: 32690797
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals, PMID: 28643356
Apitherapy for Age-Related Skeletal Muscle Dysfunction (Sarcopenia): A Review on the Effects of Royal Jelly, Propolis, and Bee Pollen, PMID: 32992744
Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy, PMID: 28905498
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study, PMID: 28653345
Treatment of sporadic inclusion body myositis with bimagrumab, PMID: 25381300
Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS, PMID: 29226558
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT, PMID: 33597289
Does Activin Receptor Blockade by Bimagrumab (BYM338) Pose Detrimental Effects on Bone Healing in a Rat Fibula Osteotomy Model?, PMID: 27167138
[Neurology], PMID: 26946707
Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial, PMID: 30095981
Therapeutic potential of muscle growth promoters in a stress urinary incontinence model, PMID: 32686522
Inclusion body myositis: update, PMID: 25215417
Diagnosis and Management of Immune-Mediated Myopathies, PMID: 28473041
Antibodies to watch in 2015, PMID: 25484055
Novel therapeutic options for cachexia and sarcopenia, PMID: 27382931
Novel investigational biologics for the treatment of cancer cachexia, PMID: 24707881
Mechanisms of skeletal muscle ageing; avenues for therapeutic intervention, PMID: 24880707
Blocking the activin IIB receptor with bimagrumab (BYM338) increases walking performance: A meta-analysis, PMID: 34405505
Muscle-bone interactions: From experimental models to the clinic? A critical update, PMID: 26506009
Antibodies to watch in 2014, PMID: 24284914
New Hope for Sarcopenia, PMID: 29148043
Ongoing developments in sporadic inclusion body myositis, PMID: 25399751
Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls, PMID: 31218901
The COPD Pipeline XXXII, PMID: 28848893
No longer going to waste, PMID: 27153267
Antibodies to watch in 2016, PMID: 26651519
Reply to: New Hope for Sarcopenia, PMID: 29148045
[Late phase II/III study of BYM338 in patients with sporadic inclusion body myositis (RESILIENT): Japanese cohort data], PMID: 31761834
Endpoint choice for inclusion body myositis: a step too far?, PMID: 31397280
Challenges for Treatment Trials of Inclusion Body Myositis, PMID: 33597288
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy, PMID: 29109273
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments, PMID: 27462398
An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy, PMID: 24298022
Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs, PMID: 26842585
Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults, PMID: 34165376
Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy, PMID: 29726548
Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force, PMID: 27883164
For research use only. Not for human or drug use.
